Changes in Beneficial Ownership · 4
MapLight Therapeutics, Inc.
MPLTNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-10162026_051008.xml
Filing details
- Report period
- 2026-10-15
- Issuer
- MapLight Therapeutics, Inc.
- Issuer CIK
- 0001770069
- Trading symbol
- MPLT
Reporting owner 1
- Name
- Lillie James Woodruff
- Reporting owner CIK
- 0001728746
- Relationship
- Officer
- Officer title
- Chief Scientific Officer
- Address
- C/O MAPLIGHT THERAPEUTICS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Voting Common Stock | 2026-10-15 | S · Form 4 | 11,513[F1] | D | 8.08[F2] | 198,597 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.↩ 1
- F2
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.755 to $8.3732 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.↩ 1
Signature 1
- Signed
- /s/ Kristopher L. Hanson, Attorney-in-Fact
- Date
- 2026-10-16
Company context
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. We believe our deep understanding of these causal links between the modulation of defined neural circuits and the resulting changes in disease-specific behaviors will enable us to develop therapeutics that can deliver efficacy, safety, tolerability and ease-of-use advantages to patients and prescribers.